US2010256341A1PendingUtilityA1

Treatment of inflammation using alpha 7 receptor-binding cholinergic agonists

56
Individually held — no corporate assignee on recordPriority: Dec 6, 2002Filed: Jun 18, 2010Published: Oct 7, 2010
Est. expiryDec 6, 2022(expired)· nominal 20-yr term from priority
Inventors:Kevin J. TraceyHong Wang
A61P 29/00G01N 33/6863G01N 2333/525A61K 31/46A61K 31/444A61K 31/439A61K 31/00A61P 1/18G01N 2333/54G01N 33/9406Y02A50/30
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Claims

exact text as granted — not AI-modified
1 . An agonist antibody that selectively binds an α7 nicotinic receptor, wherein said agonist antibody inhibits release of a proinflammatory cytokine from a mammalian cell. 
     
     
         2 . The antibody of  claim 1 , wherein the proinflammatory cytokine is selected from the group consisting of tumor necrosis factor (TNF), interleukin (IL)-1β, IL-6, IL-18 and HMG-1. 
     
     
         3 . The antibody of  claim 2 , wherein the proinflammatory cytokine is TNF. 
     
     
         4 . The antibody of  claim 1 , wherein the mammalian cell is an immune cell. 
     
     
         5 . The antibody of  claim 1 , wherein the mammalian cell is a macrophage. 
     
     
         6 . The antibody of  claim 1 , wherein the mammalian cell is treated with an agent that stimulates a proinflammatory cytokine cascade. 
     
     
         7 . The antibody of  claim 6 , wherein the agent is LPS. 
     
     
         8 . The antibody of  claim 1 , wherein the antibody is a polyclonal antibody. 
     
     
         9 . The antibody of  claim 1 , wherein the antibody is a monoclonal antibody.

Join the waitlist — get patent alerts

Track US2010256341A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.